Trevi Therapeutics (TRVI) Other financing activities (2018 - 2026)
Trevi Therapeutics (TRVI) posted quarterly Other financing activities of $222000.0 for Q1 2026, down 69.08% year-over-year from $718000.0 in Q1 2025, and up 102.56% quarter-over-quarter from -$8.7 million in Q4 2025.
Trevi Therapeutics (TRVI) Other financing activities (2018 - 2026) Analysis & Trends
Trevi Therapeutics' Other financing activities history runs 9 years deep, the most recent figure standing at $222000.0 for Q1 2026.
- In Q1 2026, Other financing activities fell 69.08% year-over-year to $222000.0; the TTM figure through Mar 2026 stood at $1.6 million (up 42.87% YoY), while the FY2025 annual figure was $2.1 million, up 427.66% from the prior year.
- Other financing activities for Q1 2026 stood at $222000.0, up from -$8.7 million in the prior quarter.
- The five-year high for Other financing activities was $10.0 million in Q2 2025, with the low at -$8.7 million in Q4 2025.
- The 5-year median for Other financing activities is $41000.0 (2023), against an average of $193866.7.
- Peak annual rise in Other financing activities reached 33363.33% in 2025, while the deepest fall reached 66853.85% in 2025.
- Trevi Therapeutics' Other financing activities stood at $116000.0 in 2022, then tumbled by 64.66% to $41000.0 in 2023, then plunged by 68.29% to $13000.0 in 2024, then slumped by 66853.85% to -$8.7 million in 2025, then surged by 102.56% to $222000.0 in 2026.
- Business Quant data shows TRVI's Other financing activities at $222000.0 in Q1 2026, -$8.7 million in Q4 2025, and $10.0 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Trevi Therapeutics | 2.63 Bn | 2.63 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.72 Mn |
| Jun 30, 2026 | 1.72 Mn |
| Mar 31, 2026 | 222,000.00 |
| Mar 31, 2026 | 222,000.00 |
| Dec 31, 2025 | -8.68 Mn |
| Dec 31, 2025 | -8.68 Mn |
| Jun 30, 2025 | 10.04 Mn |
| Jun 30, 2025 | 10.04 Mn |
| Mar 31, 2025 | 718,000.00 |
| Mar 31, 2025 | 718,000.00 |
| Dec 31, 2024 | 13,000.00 |
| Dec 31, 2024 | 13,000.00 |
| Sep 30, 2024 | 347,000.00 |
| Sep 30, 2024 | 347,000.00 |
| Jun 30, 2024 | 30,000.00 |
| Jun 30, 2024 | 30,000.00 |
| Mar 31, 2024 | 4,000.00 |
| Mar 31, 2024 | 4,000.00 |
| Dec 31, 2023 | 41,000.00 |
| Dec 31, 2023 | 41,000.00 |